Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2Stomach Neoplasms 1Solid Tumor 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 56Capecitabine 49Fluorouracil 37Cisplatin 37S 1 (combination) 23Paclitaxel 18Docetaxel 18Leucovorin 16pembrolizumab 13Irinotecan 12apatinib 11titanium silicide 9XELOX 9Trastuzumab 9Nivolumab 9Hyperthermic Intraperitoneal Chemotherapy 8Epirubicin 8Drug Therapy 8Tegafur 7Radiotherapy 6Neoadjuvant Therapy 6gimeracil 5Surgical Procedures, Operative 5Gastrectomy 5Chemotherapy, Adjuvant 5tislelizumab 4S-1 plus cisplatin 4Ramucirumab 4zolbetuximab 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Stomach Neoplasms × onartuzumab × Clear all
NCT01662869 2016-11-02

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Hoffmann-La Roche

Phase 3 Completed
564 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡